PracticeVideosBlogFlashcardsEspañol
All Practice Exams

100+ Free Revalida Farmacia UChile Practice Questions

Prepare for the Examen de Revalidación de Título de Químico Farmacéutico (Universidad de Chile) exam with instant access — no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More Chile Professional Degree Revalidation Examinations (Universidad de Chile / D.F.L. N° 153 / D.S. N° 174)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Chile Cirujano Dentista Revalidation Examination (Universidad de Chile)

Practice Questions

Chile Enfermera(o) Revalidation Examination (Universidad de Chile)

Practice Questions

Chile Kinesiólogo(a) Revalidation Examination (Universidad de Chile)

Practice Questions

Chile Tecnólogo(a) Médico(a) Revalidation Examination — Bioanálisis Clínico (Universidad de Chile)

Practice Questions
2026 Statistics

Key Facts: Revalida Farmacia UChile Exam

17 UTM

Total Process Fee

Facultad de Ciencias Químicas y Farmacéuticas UChile

4.0 / 7.0

Passing Mark Per Area

Escuela de Pregrado Facultad Cs. Químicas y Farmacéuticas

10 Disciplines

Official Scope

Facultad Cs. Químicas y Farmacéuticas Calendario de Exámenes

3 Attempts

Maximum Allowed

Reglamento General de Revalidación Universidad de Chile

2 Years

Process Time Limit

Reglamento de Revalidación Facultad Cs. Químicas y Farmacéuticas

2 Days

Exam Schedule

Facultad Cs. Químicas y Farmacéuticas UChile

Código Sanitario Libro IV

Legal Framework

Biblioteca del Congreso Nacional de Chile (BCN)

ISP / ANAMED

Regulatory Body

Instituto de Salud Pública de Chile

The Universidad de Chile Pharmacist Revalidation Exam is a standardized written examination across 10 core pharmaceutical disciplines under D.F.L. N° 153/1981 and D.S. N° 174/2024. It costs 17 UTM total, requires a passing grade of 4.0/7.0 in each independent discipline, covers both industrial and clinical pharmacy, and allows up to 3 attempts within 2 years.

Sample Revalida Farmacia UChile Practice Questions

Try these sample questions to test your Revalida Farmacia UChile exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1What is the primary molecular mechanism of action of Angiotensin-Converting Enzyme (ACE) inhibitors (e.g., Enalapril) in reducing blood pressure and preventing adverse left ventricular remodeling in heart failure?
A.Inhibits ACE (peptidyl dipeptidase), blocking the conversion of Angiotensin I to Angiotensin II while simultaneously preventing the degradation of vasodilatory bradykinin
B.Competitively blocks AT1 angiotensin receptors without affecting bradykinin levels
C.Directly stimulates renal beta-1 adrenergic receptors
D.Blocks voltage-gated L-type calcium channels in vascular smooth muscle
Explanation: ACE inhibitors competitively block the zinc metalloproteinase ACE (kininase II). This suppresses the synthesis of the potent vasoconstrictor and aldosterone-secretagogue Angiotensin II, while inhibiting bradykinin degradation (elevated bradykinin promotes nitric oxide/prostacyclin vasodilation but also causes the characteristic dry cough).
2Which antimicrobial agent inhibits bacterial cell wall synthesis by binding with high affinity to the D-alanyl-D-alanine terminus of peptidoglycan precursor pentapeptides, preventing transglycosylase polymerization and transpeptidase cross-linking?
A.Vancomycin (Glycopeptide)
B.Amoxicillin (Aminopenicillin)
C.Gentamicin (Aminoglycoside)
D.Ciprofloxacin (Fluoroquinolone)
Explanation: Vancomycin is a bactericidal glycopeptide that binds directly to the D-Ala-D-Ala terminus of cell wall peptidoglycan precursors, sterically blocking both transglycosylation and transpeptidation. It is active against Gram-positive bacteria, including MRSA.
3A patient stabilized on chronic warfarin therapy is prescribed oral Fluconazole for esophageal candidiasis. What pharmacokinetic drug interaction occurs, and what clinical outcome is anticipated?
A.Fluconazole strongly inhibits hepatic CYP2C9 (the primary metabolic enzyme for the more potent S-warfarin isomer), markedly increasing warfarin plasma concentrations and significantly elevating INR, leading to severe bleeding risk
B.Fluconazole induces CYP3A4, accelerating warfarin metabolism and decreasing INR
C.Fluconazole binds warfarin in the gut lumen, completely blocking its oral absorption
D.Fluconazole has zero effect on warfarin metabolism
Explanation: Warfarin is administered as a racemic mixture; the S-enantiomer is 3–5 times more potent than R-warfarin and is cleared predominantly by CYP2C9. Azole antifungals (fluconazole) are potent CYP2C9 inhibitors, causing dramatic warfarin accumulation, elevated INR, and major hemorrhage. Warfarin dose must be preemptively reduced and INR monitored closely.
4What is the molecular mechanism of action of Direct Oral Anticoagulants (DOACs) such as Rivaroxaban, Apixaban, and Edoxaban?
A.Direct, selective, reversible competitive inhibition of free and clot-bound Factor Xa
B.Direct competitive inhibition of Thrombin (Factor IIa)
C.Inhibition of Vitamin K Epoxide Reductase Complex 1 (VKORC1)
D.Irreversible inhibition of platelet cyclooxygenase-1 (COX-1)
Explanation: Rivaroxaban, Apixaban, and Edoxaban are direct Factor Xa inhibitors ('xabans') that bind directly to the active catalytic site of Factor Xa without requiring antithrombin III as a cofactor, blocking prothrombin conversion to thrombin.
5Which antidiabetic drug class acts by selectively inhibiting the Sodium-Glucose Co-transporter 2 (SGLT2) in the proximal renal tubules, promoting urinary glucose excretion and demonstrating proven cardioprotective and nephroprotective benefits?
A.SGLT2 inhibitors / Gliflozins (e.g., Dapagliflozin, Empagliflozin)
B.Sulfonylureas (e.g., Glibenclamide)
C.Thiazolidinediones / Glitazones (e.g., Pioglitazone)
D.DPP-4 inhibitors / Gliptins (e.g., Sitagliptin)
Explanation: SGLT2 inhibitors (Dapagliflozin, Empagliflozin) block high-capacity glucose reabsorption in the S1 segment of proximal renal tubules, inducing glucosuria, osmotic diuresis, blood pressure reduction, and significant mortality reduction in heart failure (HFrEF/HFpEF) and chronic kidney disease.
6What is the primary mechanism of action of Proton Pump Inhibitors (PPIs, e.g., Omeprazole) in suppressing gastric acid secretion?
A.Prodrug that accumulates in acidic parietal cell canaliculi, undergoes acid-activated conversion to a reactive sulfenamide, and covalently binds via disulfide bonds to the H+/K+-ATPase pump, irreversibly inactivating it
B.Competitive reversible antagonism of histamine H2 receptors on parietal cells
C.Direct chemical neutralization of hydrochloric acid in the gastric lumen
D.Activation of mucosal prostaglandin EP3 receptors
Explanation: Omeprazole is a weak base prodrug that concentrates in the highly acidic secretory canaliculi of parietal cells (pH <2). It is protonated into a tetracyclic sulfenamide that forms a covalent disulfide bond with cysteine residues on the H+/K+-ATPase (proton pump), providing irreversible acid suppression lasting 24–48 hours until new pumps are synthesized.
7Which adverse effect is classically associated with Aminoglycoside antibiotics (e.g., Gentamicin, Amikacin) and mandates routine Therapeutic Drug Monitoring (TDM)?
A.Concentration- and time-dependent Nephrotoxicity (acute tubular necrosis) and Ototoxicity (irreversible vestibular and cochlear hair cell damage)
B.Aplastic anemia and Gray Baby Syndrome
C.Severe pulmonary fibrosis and corneal microdeposits
D.Achilles tendon rupture and QT prolongation
Explanation: Aminoglycosides accumulate in renal proximal tubular cells (causing reversible non-oliguric acute tubular necrosis) and inner ear perilymph/endolymph (causing progressive, irreversible destruction of sensory hair cells: cochlear hearing loss and vestibular ataxia). Monitoring trough concentrations prevents accumulation toxicity.
8What is the pharmacological rationale for combining Levodopa with Carbidopa (or Benserazide) in the treatment of Parkinson's Disease?
A.Carbidopa is an extracerebral (peripheral) DOPA-decarboxylase inhibitor that does not cross the blood-brain barrier, preventing peripheral conversion of levodopa to dopamine, thereby increasing central brain bioavailability and reducing peripheral nausea and cardiac arrhythmias
B.Carbidopa directly stimulates dopamine D2 receptors in the striatum
C.Carbidopa is a central MAO-B inhibitor that prevents dopamine degradation in the cortex
D.Carbidopa chemically neutralizes levodopa toxicity in the liver
Explanation: Dopamine cannot cross the blood-brain barrier, but Levodopa can via L-amino acid transporters. Carbidopa inhibits peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) without entering the CNS, boosting Levodopa delivery across the BBB from ~1% to >10% while eliminating peripheral dopamine side effects (severe emesis, orthostasis, tachycardia).
9Which antineoplastic monoclonal antibody specifically targets the Human Epidermal Growth Factor Receptor 2 (HER2/neu / ErbB2) extracellular domain in HER2-positive breast and gastric cancers?
A.Trastuzumab
B.Rituximab
C.Bevacizumab
D.Infliximab
Explanation: Trastuzumab (Herceptin) is a humanized IgG1 monoclonal antibody targeting the extracellular domain IV of the HER2 receptor, blocking downstream PI3K/Akt signaling, arresting cell cycle, and recruiting antibody-dependent cellular cytotoxicity (ADCC). (Cardiotoxicity must be monitored).
10What is the primary mechanism of action of Statin drugs (e.g., Atorvastatin, Rosuvastatin) in lowering serum LDL cholesterol?
A.Competitive inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, depleting intracellular hepatic cholesterol and upregulating cell-surface LDL receptors to clear circulating LDL from blood
B.Direct binding of bile acids in the small intestine to prevent enterohepatic recycling
C.Inhibition of the Niemann-Pick C1-Like 1 (NPC1L1) intestinal cholesterol transporter
D.Activation of Peroxisome Proliferator-Activated Receptor-alpha (PPAR-alpha)
Explanation: Statins are structural analogues of HMG-CoA that competitively inhibit HMG-CoA reductase (the rate-limiting enzyme in de novo cholesterol biosynthesis). Decreased hepatocyte cholesterol activates SREBP-2, which dramatically upregulates LDL receptor transcription, increasing clearance of atherogenic ApoB/LDL particles from circulation.

About the Revalida Farmacia UChile Exam

The Examen de Revalidación de Título de Químico Farmacéutico is the standardized examination administered by the Facultad de Ciencias Químicas y Farmacéuticas of the Universidad de Chile to certify the professional equivalence of foreign pharmacy degrees under D.F.L. N° 153 of 1981 and Decreto Supremo N° 174 of 2024 MINEDUC. In Chile, Químicos Farmacéuticos hold statutory authority over the preparation, quality control, dispensing, and pharmacovigilance of pharmaceutical and cosmetic products under Book IV of the Sanitary Code (Código Sanitario). The examination is structured across 10 official disciplines covering the entire breadth of pharmaceutical science. Language and format disclosure: the real examination is administered in person in Santiago in Spanish. This bank is an English-language multiple-choice study adaptation designed to master the pharmacological, biopharmaceutic, formulation, and Chilean regulatory concepts tested on the official examination.

Assessment

The examination is delivered over two days across 10 official disciplines: Day 1 covers Farmacología Clínica, Toxicología, Farmacoquímica, Farmacia Comunitaria, and Salud Pública; Day 2 covers Tecnología Farmacéutica, Tecnología Cosmética, Farmacia Asistencial, Biofarmacia y Farmacocinética, and Legislación Farmacéutica. Each discipline is graded independently on a 1.0–7.0 scale with a passing threshold of 4.0.

Time Limit

Two-day examination schedule with morning and afternoon testing sessions

Passing Score

Grade 4.0 or higher (scale 1.0–7.0) on each of the 10 individual disciplines

Exam Fee

17 UTM total (2 UTM Prorrectoría + 3 UTM antecedentes study + 12 UTM examination) (Universidad de Chile — Facultad de Ciencias Químicas y Farmacéuticas (under D.U. Exento N° 0030.203, D.F.L. N° 153 of 1981, and D.S. N° 174 of 2024 MINEDUC))

Revalida Farmacia UChile Exam Content Outline

Not published

Farmacología Clínica

Cardiovascular, neurological, antimicrobial, endocrine and antineoplastic pharmacology; receptor and enzyme mechanisms; adverse drug reactions; and clinically significant interactions such as CYP2C9 inhibition of warfarin. Examined in Bloque 01 on day one alongside Toxicología.

Not published

Toxicología

Toxidrome recognition, paracetamol poisoning and the N-acetylcysteine protocol, organophosphate poisoning with atropine and pralidoxime, toxic alcohols and fomepizole, methaemoglobinaemia, tricyclic cardiotoxicity, cyanide, and heavy-metal chelation.

Not published

Farmacoquímica

Structure-activity relationships of the major drug classes, bioisosterism, prodrug strategy, Lipinski's rule of five, pKa and partition behaviour, and hepatic Phase I and Phase II metabolic pathways. Examined in Bloque 02 alongside Farmacia Comunitaria.

Not published

Farmacia Comunitaria

Prescription verification and validity, dispensing counselling and interaction screening, bioequivalent generic substitution and the ISP bioequivalence seal, storage and cold-chain advice, inhaler and insulin technique, and the legal duties of the Director Técnico under D.S. N° 466/82.

Not published

Salud Pública

Incidence and prevalence, diagnostic test performance, cost-effectiveness analysis, infant mortality and other Chilean health indicators, the Programa Nacional de Inmunizaciones and cold chain, the Programa de Salud Cardiovascular, CENABAST, food labelling under Ley N° 20.606, and antimicrobial stewardship. Examined alone in Bloque 03.

Not published

Tecnología Farmacéutica

Tablet and capsule formulation, excipient roles, compression defects, enteric and modified-release coating, the Noyes-Whitney dissolution relationship, GMP/BPF cleanroom grades, sterilisation and biological indicators, endotoxin testing, and ICH Q1A stability conditions for Climatic Zone IVb. Examined in Bloque 04 alongside Tecnología Cosmética.

Not published

Tecnología Cosmética

Emulsion type and HLB selection, physical instability modes, rheology modifiers and gelling polymers, humectants, organic and mineral UV filters, SPF determination, alpha-hydroxy acids, preservative efficacy challenge testing, and the cosmetic definition and control system under D.S. N° 239/02.

Not published

Farmacia Asistencial

Unit-dose distribution (SDMUD), parenteral nutrition compounding and calcium-phosphate incompatibility, cytotoxic compounding containment, therapeutic drug monitoring of vancomycin and aminoglycosides, medication reconciliation, formulary and restriction policy, and inventory control. Examined in Bloque 05 alongside Biofarmacia y Farmacocinética.

Not published

Biofarmacia y Farmacocinética

Clearance, volume of distribution, half-life and steady state, loading-dose calculation, absolute bioavailability, Michaelis-Menten non-linear elimination, the Biopharmaceutics Classification System, bioequivalence acceptance criteria, P-glycoprotein efflux, and Cockcroft-Gault renal dose adjustment.

Not published

Legislación Farmacéutica

Código Sanitario Libro IV, D.S. N° 3/2010 on registro sanitario and magistral/oficinal compounding, D.S. N° 404/83 and D.S. N° 405/83 on narcotics and psychotropics and the receta cheque, farmacias de turno under Article 129, the Ley de Fármacos prohibition on sales incentives, and the Farmacopea Chilena. Examined alone in Bloque 06.

How to Pass the Revalida Farmacia UChile Exam

What You Need to Know

  • Passing score: Grade 4.0 or higher (scale 1.0–7.0) on each of the 10 individual disciplines
  • Assessment: The examination is delivered over two days across 10 official disciplines: Day 1 covers Farmacología Clínica, Toxicología, Farmacoquímica, Farmacia Comunitaria, and Salud Pública; Day 2 covers Tecnología Farmacéutica, Tecnología Cosmética, Farmacia Asistencial, Biofarmacia y Farmacocinética, and Legislación Farmacéutica. Each discipline is graded independently on a 1.0–7.0 scale with a passing threshold of 4.0.
  • Time limit: Two-day examination schedule with morning and afternoon testing sessions
  • Exam fee: 17 UTM total (2 UTM Prorrectoría + 3 UTM antecedentes study + 12 UTM examination)

Keys to Passing

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

Revalida Farmacia UChile Study Tips from Top Performers

1Thoroughly review Chilean pharmaceutical regulations: Código Sanitario (Libro IV), D.S. N° 466/82 (Reglamento de Farmacias), D.S. N° 404/83 (Estupefacientes), D.S. N° 405/83 (Psicotrópicos), and Ley de Fármacos I & II.
2Master pharmacokinetic calculations: clearance (CL = Dose / AUC), volume of distribution (Vd = Dose / C0), elimination rate constant (ke = CL / Vd), half-life (t1/2 = 0.693 / ke), and steady-state concentration (Css = R0 / CL).
3Understand the Biopharmaceutics Classification System (BCS Classes I–IV) and Chilean ISP bioequivalence criteria for generic substitution.
4Review antidote protocols in clinical toxicology: N-acetylcysteine for paracetamol, pralidoxime/atropine for organophosphates, naloxone for opioids, flumazenil for benzodiazepines, and chelators (dimercaprol, DMSA, deferoxamine).
5Study industrial tablet formulation: binders, disintegrants, lubricants, glidants, film coatings, and cleanroom air handling standards (GMP/BPF).
6Understand hospital pharmacy systems: Sistema de Distribución de Medicamentos por Dosis Unitaria (SDMUD), sterile compounding of Total Parenteral Nutrition (TPN), and therapeutic drug monitoring (TDM).

Frequently Asked Questions

What is the Universidad de Chile Pharmacist Revalidation Exam?

It is the standardized examination administered by the Facultad de Ciencias Químicas y Farmacéuticas at Universidad de Chile under D.F.L. N° 153 of 1981 and Decreto Supremo N° 174 of 2024 to revalidate foreign pharmacy degrees and grant the Chilean professional title of Químico Farmacéutico.

Who is required to take this revalidation examination?

Foreign-trained pharmacists and pharmaceutical scientists who graduated outside Chile and wish to practice legally in Chile, manage community or hospital pharmacies as Technical Directors (Directores Técnicos), work in pharmaceutical industry, or register with the Superintendencia de Salud, other than those qualifying for direct treaty recognition through Minrel.

What is the structure of the examination?

The examination is divided across 10 official disciplines tested over two days: Farmacología Clínica, Toxicología, Farmacoquímica, Farmacia Comunitaria, Salud Pública, Tecnología Farmacéutica, Tecnología Cosmética, Farmacia Asistencial, Biofarmacia y Farmacocinética, and Legislación Farmacéutica. Each discipline is evaluated and passed independently with a grade of >=4.0 on the 1.0–7.0 scale.

What are the fees for pharmacist revalidation in Chile?

The fees at the Facultad de Ciencias Químicas y Farmacéuticas comprise 2 UTM for initial intake at Prorrectoría, 3 UTM for the faculty study of antecedentes, and 12 UTM for the examination across 10 disciplines (17 UTM total). Upon passing, diploma issuance costs $52.000 CLP and certificate issuance costs $26.000 CLP.

How many attempts are permitted?

Candidates are allowed up to three attempts in total. All examinations must be completed within two years of acceptance into the process.

Is this practice bank in Spanish or English?

This bank is an English-language multiple-choice study adaptation designed to master the clinical, formulation, biopharmaceutic, and regulatory concepts tested on the exam. The official Chilean examination is conducted in person in Spanish.